ClinicalTrials.Veeva

Menu

CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer

Pfizer logo

Pfizer

Status and phase

Completed
Phase 2

Conditions

Carcinoma, Breast

Treatments

Drug: 0.08 mg/kg CpG 7909
Drug: 0.04 mg/kg CpG 7909
Drug: Herceptin®
Drug: 0.16 mg/kg CpG 7909
Drug: 0.12 mg/kg CpG 7909

Study type

Interventional

Funder types

Industry

Identifiers

NCT00043394
A8501021, CO15
C015

Details and patient eligibility

About

To determine the safety and efficacy of CPG 7909 Injection given with Herceptin to patients with metastatic breast cancer.

Enrollment

16 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histologically confirmed breast cancer with metastases
  • Tumor that has overexpression of HER2 as documented by being either FISH-positive or HER2/neu 3+ confirmed by immunohistochemistry
  • Patients may have had up to three prior chemotherapy regimens for metastatic disease, which may have been given in combination with Herceptin® and which may have been discontinued due to toxicities. In addition, patients may have had adjuvant chemotherapy.
  • Phase II only: Must have measurable disease by RECIST criteria (defined in section 8) with at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques, or as > 10 mm with spiral CT scan

Exclusion criteria

  • Any prior therapy with anthracycline + Herceptin® concurrently
  • Significant cardiovascular disease (e.g., NYHA class 3 congestive heart failure, myocardial infarction within the past 6 months, unstable angina; coronary angioplasty within the past 6 months, uncontrolled atrial or ventricular cardiac arrhythmias) or left ventricular ejection fraction < 50%
  • Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

16 participants in 4 patient groups

Cohort 1
Experimental group
Description:
0.04 mg/kg CpG 7909
Treatment:
Drug: Herceptin®
Drug: 0.04 mg/kg CpG 7909
Drug: Herceptin®
Drug: Herceptin®
Drug: Herceptin®
Cohort 2
Experimental group
Description:
0.08 mg/kg CpG 7909
Treatment:
Drug: Herceptin®
Drug: 0.08 mg/kg CpG 7909
Drug: Herceptin®
Drug: Herceptin®
Drug: Herceptin®
Cohort 3
Experimental group
Description:
0.12 mg/kg CpG 7909 Injection once weekly
Treatment:
Drug: 0.12 mg/kg CpG 7909
Drug: Herceptin®
Drug: Herceptin®
Drug: Herceptin®
Drug: Herceptin®
Cohort 4
Experimental group
Description:
0.16 mg/kg CpG 7909
Treatment:
Drug: 0.16 mg/kg CpG 7909
Drug: Herceptin®
Drug: Herceptin®
Drug: Herceptin®
Drug: Herceptin®

Trial contacts and locations

12

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems